195733-43-8

Basic information

• Product Name: (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride
• Synonyms: 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, monohydrochloride, (2R,3R,4S)-;A 147627.1;Abbott 147627;Atrasentan HCl;Atrasentan hydrochloride [usan];Unii-E4G31X93za;ABT 627;ABT627
• CAS NO: 195733-43-8
• Molecular Formula: C29H38N2O6.HCl
• Molecular Weight: 547.08
• Product Categories: Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 195733-43-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 659.4°Cat760mmHg
• Flash Point: 352.6°C
• Appearance: /
• Density: 1.238g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride(195733-43-8)
• EPA Substance Registry System: (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride(195733-43-8)

Safety Data

• Hazardous Substances Data: 195733-43-8(Hazardous Substances Data)

Usage

Uses

Atrasentan, a selective antagonist of the endothelin-A (ETA) receptor, binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.

InChI:InChI=1/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1

Upstream product

• 1563-90-2 N,N-dibutylacetamide 
• 2861-28-1 1,3-benzodioxole-5-acetic acid 
• 250583-00-7 (S)-2-Benzo[1,3]dioxol-5-yl-succinic acid 4-tert-butyl ester 
• 250261-64-4 2-(3,4-Methylenedioxyphenyl)acetic pivalic anhydride 
• 250583-01-8 3-benzo[1,3]dioxol-5-yl-4-hydroxy-butyric acid tert-butyl ester 
• 179390-12-6 (4''S)-isopropyl-2''-oxazolidino-N-(3',4'-methylenedioxy) phenylacetate 
• 250583-09-6 (2R,3R,4S)-4-Benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid methyl ester 
• 250583-05-2 (S)-3-Benzo[1,3]dioxol-5-yl-4-[1-(4-methoxy-phenyl)-meth-(E)-ylideneaminooxy]-butyric acid methyl ester 
• 250583-08-5 (2R,3S)-2-[(R)-Amino-(4-methoxy-phenyl)-methyl]-3-benzo[1,3]dioxol-5-yl-4-hydroxy-butyric acid methyl ester 
• 173937-91-2 atrasentan 
• 1485-00-3 5-((E)-2-nitroethenyl)-1,3-benzodioxole 
• 40124-27-4 N,N-dibutylbromoacetamide 
• 2881-83-6 ethyl 4-methoxybenzoylacetate 
• 173864-47-6 ethyl trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylate 

Relevant articles and documents

Preparation of endothelin antagonist ABT-627

An enantioselective synthesis of ABT-627 is described. The key transformation is a diastereoselective 6-endo-trig cyclization to produce a 3,4,5-trisubstituted-1,2-oxazine which is ring contracted to the 2,3,4-tri-substituted-pyrrolidine core of ABT-627.

CRYSTALLINE FORM OF ATRASENTAN HYDROCHLORIDE

Substantially amorphous atrasentan hydrochloride, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Crystalline form of a drug

Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.